MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: The association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib

Molecular Carcinogenesis

Volumn 53, Issue 12, 2014, Pages 951-959

  Liu, Yi Chang ^a,b   Hsiao, Hui Hua ^a,b   Yang, Wen Chi ^a,b   Liu, Ta Chih ^a,b   Chang, Chao Sung ^a,b   Yang, Ming Yu ^c   Lin, Pai Mei ^d   Hsu, Jui Feng ^a   Lee, Ching Ping ^a   Lin, Sheng Fung ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d I SHOU UNIVERSITY   (Taiwan)

Author keywords

Chronic myeloid leukemia; Imatinib; MDM2; P53; Polymorphism

Indexed keywords

IMATINIB; PROTEIN MDM2; PROTEIN P53; BENZAMIDE DERIVATIVE; CODON; MDM2 PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; ALLELE; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CHRONIC MYELOID LEUKEMIA; CODON; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIMARY HEALTH CARE; PROMOTER REGION; PROTEIN POLYMORPHISM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; UNIVERSITY HOSPITAL; ASIAN CONTINENTAL ANCESTRY GROUP; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED;

ADULT; AGE OF ONSET; ASIAN CONTINENTAL ANCESTRY GROUP; BENZAMIDES; CASE-CONTROL STUDIES; CODON; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MDM2; PYRIMIDINES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84911427210     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22061     Document Type: Article

References (42)

1. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88:323-331.
2. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-310.
3. Jin S, Levine AJ. The p53 functional circuit. J Cell Sci 2001; 114:4139-4140.
4. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69:1237-1245.
5. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997; 420:25-27.
6. Iwakuma T, Lozano G. MDM2. An introduction. Mol Cancer Res 2003; 1:993-1000.
7. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358:80-83.
8. Rayburn E, Zhang R, He J, Wang H. MDM2 and human malignancies: Expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets 2005; 5:27-41.
9. Dumont P, Leu JI, Della Pietra AC III, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003; 33:357-365.
10. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999; 19:1092-1100.
11. Hrstka R, Coates PJ, Vojtesek B. Polymorphisms in p53 and the p53 pathway: Roles in cancer susceptibility and response to treatment. J Cell Mol Med 2009; 13:440-453.
12. Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: Cancer implications. Nat Rev Cancer 2009; 9:95-107.
13. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119:591-602.
14. Quintás-Cardama A, Cortes J. Molecular biology of BCR-ABL1-positive chronic myeloid leukemia. Blood 2009; 113:1619-1630.
15. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27:6041-6051.
16. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004; 103:4010-4022.
17. Perrotti D, Jamieson C, Goldman J, Skorski T. Chronic myeloid leukemia: Mechanisms of blastic transformation. J Clin Invest 2010; 120:2254-2264.
18. Ahuja H, Bar-Eli M, Advani SH, Benchimol S, Cline MJ. Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proc Natl Acad Sci USA 1989; 86:6783-6787.
19. Feinstein E, Cimino G, Gale RP, et al. p53 in chronic myelogenous leukemia in acute phase. Proc Natl Acad Sci USA 1991; 88:6293-6297.
20. Honda H, Ushijima T, Wakazono K, et al. Acquired loss of p53 induces blastic transformation in p210(BCR/ABL)-expressing hematopoietic cells: A transgenic study for blast crisis of human CML. Blood 2000; 95:1144-1150.
21. Skorski T, Nieborowska-Skorska M, Wlodarski P, et al. Blastic transformation of p53-deficient bone marrow cells by p210BCR/ABL tyrosine kinase. Proc Natl Acad Sci USA 1996; 93:13137-13142.
22. Wendel HG, de Stanchina E, Cepero E, et al. Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc Natl Acad Sci USA 2006; 103:7444-7449.
23. Gryshchenko I, Hofbauer S, Stoecher M, et al. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. J Clin Oncol 2008; 26:2252-2257.
24. Kaderi MA, Mansouri M, Zainuddin N, et al. Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia. Leuk Res 2010; 34:335-339.
25. Willander K, Ungerbäck J, Karlsson K, Fredrikson M, Söderkvist P, Linderholm M. MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia. Eur J Haematol 2010; 85:251-256.
26. Zenz T, Habe S, Benner A, Kienle D, Dohner H, Stilgenbauer S. The MDM 2-309 T/G promoter single nucleotide polymorphism does not alter disease characteristics in chronic lymphocytic leukemia. Haematologica 2008; 93:1111-1113.
27. Dong HJ, Fang C, Fan L, et al. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL. Int J Cancer 2012; 130:2054-2061.
28. Ellis NA, Huo D, Yildiz O, et al. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood 2008; 112:741-749.
29. Xiong X, Wang M, Wang L, et al. Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia. Leuk Res 2009; 33:1454-1458.
30. Phillips CL, Gerbing R, Alonzo T, et al. MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer 2010; 55:248-253.
31. Swinney RM, Hsu SC, Hirschman BA, Chen TT, Tomlinson GE. MDM2 promoter variation and age of diagnosis of acute lymphoblastic leukemia. Leukemia 2005; 19:1996-1998.
32. Do TN, Ucisik-Akkaya E, Davis CF, Morrison BA, Dorak MT. TP53 R72P and MDM2 SNP309 polymorphisms in modification of childhood acute lymphoblastic leukemia susceptibility. Cancer Genet Cytogenet 2009; 195:31-36.
33. Zhuo W, Zhang L, Ling J, Zhu B, Chen Z. MDM2 SNP309 variation contributes to leukemia risk: Meta-analyses based on 7259 subjects. Leuk Lymphoma 2012; 53:2245-2252.
34. Chen YL, Chang YS, Chang JG, Wu SM. Genotyping of single nucleotide polymorphism in MDM2 genes by universal fluorescence primer PCR and capillary electrophoresis. Anal Bioanal Chem 2009; 394:1291-1297.
35. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of hematopoietic and lymphoid tissues. Lyon: IARC; 2008.
36. Langerod A, Bukholm IR, Bregard A, et al. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev 2002; 11:1684-1688.
37. Bond GL, Hirshfield KM, Kirchhoff T, et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 2006; 66:5104-5110.
38. Bergamaschi G, Merante S, Orlandi E, Galli A, Bernasconi P, Cazzola M. TP53 codon 72 polymorphism in patients with chronic myeloid leukemia. Haematologica 2004; 89:868-869.
39. Nakano Y, Naoe T, Kiyoi H, et al. Poor clinical significance of p53 gene polymorphism in acute myeloid leukemia. Leuk Res 2000; 24:349-352.
40. Kochethu G, Delgado J, Pepper C, et al. Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia. Leuk Res 2006; 30:1113-1118.
41. Trotta R, Vignudelli T, Candini O, et al. BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell 2003; 3:145-160.
42. Brusa G, Benvenuti M, Mazzacurati L, et al. p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase. Haematologica 2003; 88:622-630.